Back to Search
Start Over
Tyrosine kinase inhibitors in HER2‐positive metastatic breast cancer with trastuzumab emtansine resistance: insights from a multicenter retrospective real‐world study.
- Source :
- MedComm; Jul2024, Vol. 5 Issue 7, p1-10, 10p
- Publication Year :
- 2024
-
Abstract
- The use of trastuzumab emtansine (T‐DM1) has revealed significant efficacy in HER2‐positive metastatic breast cancer (MBC). However, optimal therapeutic strategies following T‐DM1 failure remain a subject of debate in clinical practice. In this multicenter, retrospective, real‐world study, we sought to examine the effectiveness and safety of tyrosine kinase inhibitors (TKIs) as a therapeutic strategy in HER2‐positive MBC who developed T‐DM1 resistance. Between September 2018 and December 2022, 66 patients were enrolled. The median progression‐free survival of TKIs‐based therapy was 10.1 months (95% CI, 4.7–15.6). Objective response rate and clinical benefit rate were 18.2 and 66.7%, respectively. TKIs‐based therapy demonstrated better effectiveness in patients who had previously derived benefit from T‐DM1 and featured acquired resistance to trastuzumab. The most common adverse events were diarrhea (36, 54.5%), hand‐foot syndrome (31, 47.0%), and leucopenia (30, 45.5%). In conclusion, TKIs‐based therapy showed promising effectiveness and safety in HER2‐positive MBC patients after T‐DM1 failure. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 26882663
- Volume :
- 5
- Issue :
- 7
- Database :
- Complementary Index
- Journal :
- MedComm
- Publication Type :
- Academic Journal
- Accession number :
- 178469081
- Full Text :
- https://doi.org/10.1002/mco2.624